NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Neumora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.47−0.00 (-0.80%)
Close on Oct 19, 2026
- Market cap
- $87.03M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.2600 (−72.83%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $87.03M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.95
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$212.75M
- EPS, diluted
- -$1.23
- Book value per share
- $0.24
- Diluted shares
- 185M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$211.23M
Net income
-$212.75M
EPS, diluted
-$1.23
Free cash flow
–
Reported periodTrailing twelve months